SANTA MONICA, Calif., July 7, 2025 /PRNewswire/ -- Lifeforce, the world's largest longevity medicine platform, and Toku, a health technology company using AI to translate a single retinal image into real-time biological age and cardiovascular risk scores, have announced a nationwide partnership. The collaboration will turn thousands of routine eye exams each week into powerful opportunities for early health insights and proactive intervention.
The partnership integrates Toku's BioAge™ wellness product with its forthcoming CLAiR™ technology—a recipient of the prestigious FDA Breakthrough Device designation, which is awarded to technologies that may offer more effective diagnosis or treatment of life-threatening or irreversibly debilitating conditions. CLAiR is currently on an accelerated development path, with anticipated FDA approval in 2026, and aims to transform non-invasive cardiovascular risk assessment using retinal imaging and AI.
Through this collaboration, individuals who complete a BioAge analysis—comparing their biological age to their chronological age using a retinal image—will be seamlessly connected to Lifeforce's comprehensive longevity platform. Lifeforce offers at-home diagnostics, board-certified longevity physicians, personalized protocols, and certified health coaches, enabling participants to take data-driven steps toward extending their healthspan.
"Seeing risk is only half the battle; acting on it is what changes lives," said Dugal Bain-Kim, Co-Founder and CEO of Lifeforce. "Toku delivers the earliest possible signal, and Lifeforce supplies the clinician guided programs that can slow aging, reduce cardiovascular risk, and extend healthspan."
"Partnering with Lifeforce ensures that our users are not only empowered with their health data but also supported by an elite, evidence-based longevity care team," added Ehsan Vaghefi, PhD, CEO and Co-Founder of Toku. "Together, we're enabling a proactive and accessible approach to lifelong wellbeing."
About Lifeforce
Lifeforce is the world's largest longevity-medicine platform, empowering adults to add quality years to their lives through at-home biomarker testing, direct access to expert physicians, precision lifestyle coaching, and science-backed therapies. Thousands of members across the United States have already completed more than one million biomarker tests, with 85 percent reporting quality-of-life and health outcomes improvements within six months.
About Toku
Toku, Inc. is a technology company specializing in non-invasive, AI-powered diagnostic and screening tools using retinal imaging to assess cardiovascular and other systemic health risks.
Toku's first commercial product, BioAge™, is offered in the United States as a wellness device intended to support general health awareness. It estimates an individual's biological age by analyzing biometric markers visible in the retina, helping users better understand their aging trajectory. BioAge is not intended to diagnose, treat, or prevent any disease and is not regulated as a medical device by the U.S. Food and Drug Administration (FDA).
Toku is also developing CLAiR™, a medical device platform that uses AI to assess cardiovascular risk through retinal photographs. CLAiR received Breakthrough Device designation from the FDA, and it is not yet approved for clinical use in the United States.
With a global team of scientists, engineers, and medical professionals, Toku is committed to making its cutting-edge technology accessible through strategic partnerships and trusted clinical environments.
Disclaimers
Media Contacts
Lifeforce – [email protected]
Toku Eyes – [email protected]
SOURCE Lifeforce Digital Inc.
Share this article